Target regimen profiles for tuberculosis treatment

• DOI: 10.2471/blt.24.291881
• Publication Date: 2024-08-01T08:49:01Z
• Authors: Christian Lienhardt; Kelly Dooley; Payam Nahid; Charles Wells; Theresa Ryckman; Emily Kendall; Gerry Davies; Grania Brigden; Gavin Churchyard; Daniela Maria Cir...; Eugenia Di Meco; Ramya Gopinath; Carole Mitnick; Cherise Scott; Farhana Amanullah; Cathy Bansbach; Martin Boeree; Michael Campbell; Francesca Conradie; Angela Crook; Charles Daley; Keertan Dheda; Andreas Diacon; Agnes Gebhard; Debra Hanna; Norbert Heinrich; Anneke Hesseling; David Holtzman; Mathilde Jachym; Peter Kim; Christoph Lange; Lindsay McKenna; Graeme Meintjes; Norbert Ndjeka; Nguyen Viet Nhung; Bern-Thomas Nyang’wa; Nicholas Paton; Raghuram Rao; Michael Rich; Rada Savic; Ingrid Schoeman; Boitumelo Semete ...; Mel Spigelman; Eugene Sun; Elin Svensson; Phumeza Tisile; Francis Varaine; Andrew Vernon; Mukadi Ya Diul; Tereza Kasaeva; Matteo Zignol; Medea Gegia; Fuad Mirzayev; Samuel Schumacher
• Keywords: Regimen

Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with desperately needed. In 2016, the World Health Organization (WHO) developed target regimen profiles treatment of make drug developers aware both important features regimens, patient programmatic needs at country level. view recent ground-breaking advances in treatment, WHO has revised updated these profiles. We used a similar process as 2016 profiles, including baseline landscape analysis, an initial stakeholder survey, modelling studies estimating impact cost-effectiveness novel extensive consultation. rifampicin-susceptible rifampicin-resistant tuberculosis, well pan-tuberculosis would be appropriate patients any type tuberculosis. describe profile characteristics, specific minimal optimal targets met, rationale justification, aspects relevant (drug susceptibility testing, adherence forgiveness, strategies, post-tuberculosis lung disease, cost access considerations). discuss trade-offs proposed characteristics decision-making developmental or operational levels. expect that, following revisions, will produce regimens quality-assured, affordable widely available, meet affected populations.